Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 107

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 107
---
 inventions; |

| • | others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights; |

| • | it is possible that current and future pending patent applications we own or in-license will not lead to issued patents; |

| • | issued patents that we own or in-license may not provide us with any competitive advantage, or may be held invalid or unenforceable as a result of legal challenges by third parties; |

| • | issued patents that we own or in-license may not have sufficient term or geographic scope to provide meaningful protection; |

56 Table of Contents

| • | our competitors might conduct research and development activities in countries that provide a safe harbor from patent infringement claims for certain research and development activities or in countries where we do not have patent 
 rights and then use the information learned from such activities to develop competitive therapies for sale in our major commercial markets;                                                                                           |

| • | third parties performing manufacturing or testing for us using our therapies or technologies could use the intellectual property of others without obtaining a proper license; |

| • | we may not develop additional technologies that are patentable; and |

| • | we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property, or otherwise develop similar know-how. |

Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects. We may be subject to claims by third parties asserting that we or our employees, consultants or advisors have misappropriated their intellectual property, including trade secrets, or claiming ownership of what we regard as our own intellectual property. Many of our consultants, advisors and employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Some of these individuals executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we intend that our consultants, advisors and employees do not use proprietary information or know-how of their former employers while working for us, we may be subject to claims that we or these individuals have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such individual’s former employer. Litigation may be necessary to defend against these claims, regardless of their merit, and we cannot predict whether we would prevail in any such actions. If we fail in prosecuting or